Epidemic arboviral diseases: priorities for research and public health

The Lancet Infectious Diseases

Volumn 17, Issue 3, 2017, Pages e101-e106

  Wilder Smith, Annelies ^a,b,c   Gubler, Duane J ^d   Weaver, Scott C ^e   Monath, Thomas P ^f   Heymann, David L ^g   Scott, Thomas W ^h  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b Partnership for Dengue Control   (France)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^f BioProtection Systems NewLink Genetics Corp   (United States)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; VIRUS VACCINE; YELLOW FEVER VACCINE; ZIKA VIRUS VACCINE; VACCINE;

AEDES; CHIKUNGUNYA; COST EFFECTIVENESS ANALYSIS; DENGUE; EPIDEMIC; EPIDEMIC ARBOVIRAL DISEASE; HUMAN; IMMUNE RESPONSE; MORTALITY; MOSQUITO; PRIORITY JOURNAL; PUBLIC HEALTH; RESEARCH; REVIEW; URBANIZATION; VECTOR CONTROL; VIRUS INFECTION; YELLOW FEVER; ZIKA FEVER; ZIKA VIRUS; ANIMAL; ARBOVIRUS INFECTIONS; DENGUE VIRUS; ECONOMICS; EPIDEMICS; GLOBAL HEALTH; IMMUNOLOGY; VIROLOGY;

AEDES; ANIMALS; ARBOVIRUS INFECTIONS; DENGUE VIRUS; EPIDEMICS; GLOBAL HEALTH; HUMANS; PUBLIC HEALTH; RESEARCH; VACCINES; ZIKA VIRUS;

EID: 85008210285     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30518-7     Document Type: Review

References (43)

1. 1 GBD 2013 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet 386 (2015), 2145–2191.
2. 2 Gubler, DJ, Clark, GG, Dengue/dengue hemorrhagic fever: the emergence of a global health problem. Emerg Infect Dis 1 (1995), 55–57.
3. 3 Monath, TP, Woodall, JP, Gubler, DJ, et al. Yellow fever vaccine supply: a possible solution. Lancet 387 (2016), 1599–1600.
4. 4 Khan, K, Bogoch, I, Brownstein, JS, et al. Assessing the origin of and potential for international spread of chikungunya virus from the Caribbean. PLoS Curr, 2014, 10.1371/currents.outbreaks.2134a0a7bf37fd8d388181539fea2da5 published online June 6, 2014.
5. 5 Artsob, H, Gubler, DJ, Enria, DA, et al. West Nile Virus in the New World: trends in the spread and proliferation of West Nile Virus in the Western Hemisphere. Zoonoses Public Health 56 (2009), 357–369.
6. 6 Mackenzie, JS, Gubler, DJ, Petersen, LR, Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10:suppl 12 (2004), S98–109.
7. 7 Bhatt, S, Gething, PW, Brady, OJ, et al. The global distribution and burden of dengue. Nature 496 (2013), 504–507.
8. 8 Weaver, SC, Reisen, WK, Present and future arboviral threats. Antiviral Res 85 (2010), 328–345.
9. 9 Struchiner, CJ, Rocklov, J, Wilder-Smith, A, Massad, E, Increasing dengue incidence in Singapore over the past 40 years: population growth, climate and mobility. PLoS One, 10, 2015, e0136286.
10. 10 Wilder-Smith, A, Gubler, DJ, Geographic expansion of dengue: the impact of international travel. Med Clin North Am 92 (2008), 1377–1390.
11. 11 Effler, PV, Pang, L, Kitsutani, P, et al. Dengue fever, Hawaii, 2001–2002. Emerg Infect Dis 11 (2005), 742–749.
12. 12 Renault, P, Solet, JL, Sissoko, D, et al. A major epidemic of chikungunya virus infection on Reunion Island, France, 2005–2006. Am J Trop Med Hyg 77 (2007), 727–731.
13. 13 Wong, PS, Li, MZ, Chong, CS, Ng, LC, Tan, CH, Aedes (Stegomyia) albopictus (Skuse): a potential vector of Zika virus in Singapore. PLoS Negl Trop Dis, 7, 2013, e2348.
14. 14 Reiter, P, Aedes albopictus and the world trade in used tires, 1988–1995: the shape of things to come?. J Am Mosq Control Assoc 14 (1998), 83–94.
15. 15 Kraemer, MU, Sinka, ME, Duda, KA, et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. Elife, 4, 2015, e08347.
16. 16 Liu-Helmersson, J, Stenlund, H, Wilder-Smith, A, Rocklov, J, Vectorial capacity of Aedes aegypti: effects of temperature and implications for global dengue epidemic potential. PLoS One, 9, 2014, e89783.
17. 17 Rocklov, J, Quam, M, Sudre, B, et al. Assessing seasonal risks for the introduction and mosquito-borne spread of Zika virus in Europe. EBioMedicine 9 (2016), 250–256.
18. 18 Musso, D, Gubler, DJ, Zika virus. Clin Microbiol Rev 29 (2016), 487–524.
19. 19 Heymann, DL, Hodgson, A, Sall, AA, et al. Zika virus and microcephaly: why is this situation a PHEIC?. Lancet 387 (2016), 719–721.
20. 20 Ferguson, NM, Cucunuba, ZM, Dorigatti, I, et al. Epidemiology. Countering the Zika epidemic in Latin America. Science 353 (2016), 353–354.
21. 21 Wasserman, S, Tambyah, PA, Lim, PL, Yellow fever cases in Asia: primed for an epidemic. Int J Infect Dis 48 (2016), 98–103.
22. 22 WHO. Situation report: yellow fever outbreak in Angola. http://www.afro.who.int/en/yellow-fever/sitreps/item/9085-situation-report-yellow-fever-outbreak-in-angola-29-september-2016.html, Sept 29, 2016 (accessed Oct 30, 2016).
23. 23 Mackenzie, JS, Broom, AK, Hall, RA, et al. Arboviruses in the Australian region, 1990 to 1998. Commun Dis Intell 22 (1998), 93–100.
24. 24 Gubler, DJ, Dengue, urbanization and globalization: the unholy trinity of the 21st century. Trop Med Health 39:suppl 4 (2011), 3–11.
25. 25 Tsetsarkin, KA, Chen, R, Yun, R, et al. Multi-peaked adaptive landscape for chikungunya virus evolution predicts continued fitness optimization in Aedes albopictus mosquitoes. Nat Commun, 5, 2014, 4084.
26. 26 Tsetsarkin, KA, Chen, R, Leal, G, et al. Chikungunya virus emergence is constrained in Asia by lineage-specific adaptive landscapes. Proc Natl Acad Sci USA 108 (2011), 7872–7877.
27. 27 Reiner, RC Jr, Achee, N, Barrera, R, et al. Quantifying the epidemiological impact of vector control on dengue. PLoS Negl Trop Dis, 10, 2016, e0004588.
28. 28 Bowman, LR, Donegan, S, McCall, PJ, Is dengue vector control deficient in effectiveness or evidence? Systematic review and meta-analysis. PLoS Negl Trop Dis, 10, 2016, e0004551.
29. 29 Achee, NL, Gould, F, Perkins, TA, et al. A critical assessment of vector control for dengue prevention. PLoS Negl Trop Dis, 9, 2015, e0003655.
30. 30 Louis, VR, Montenegro Quinonez, CA, Kusumawathie, P, et al. Characteristics of and factors associated with dengue vector breeding sites in the City of Colombo, Sri Lanka. Pathog Glob Health 110 (2016), 79–86.
31. 31 Andersson, N, Nava-Aguilera, E, Arostegui, J, et al. Evidence based community mobilization for dengue prevention in Nicaragua and Mexico (Camino Verde, the Green Way): cluster randomized controlled trial. BMJ, 351, 2015, h3267.
32. 32 DeRaedt Banks, S, Orsborne, J, Gezan, SA, et al. Permethrin-treated clothing as protection against the dengue vector, Aedes aegypti: extent and duration of protection. PLoS Negl Trop Dis, 9, 2015, e0004109.
33. 33 Orsborne, J, DeRaedt Banks, S, Hendy, A, et al. Personal protection of permethrin-treated clothing against Aedes aegypti, the vector of dengue and Zika virus, in the laboratory. PLoS One, 11, 2016, e0152805.
34. 34 Ritchie, SA, Devine, GJ, Confusion, knock-down and kill of Aedes aegypti using metofluthrin in domestic settings: a powerful tool to prevent dengue transmission?. Parasit Vectors, 6, 2013, 262.
35. 35 Gantz, VM, Jasinskiene, N, Tatarenkova, O, et al. Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi. Proc Natl Acad Sci USA 112 (2015), E6736–E6743.
36. 36 Wu, JT, Peak, CM, Leung, GM, Lipsitch, M, Fractional dosing of yellow fever vaccine to extend supply: a modelling study. Lancet 388 (2016), 2904–2911.
37. 37 Capeding, MR, Tran, NH, Hadinegoro, SR, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384 (2014), 1358–1365.
38. 38 Villar, L, Dayan, GH, Arredondo-Garcia, JL, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372 (2015), 113–123.
39. 39 Wilder-Smith, A, Vannice, KS, Hombach, J, Farrar, J, Nolan, T, Population perspectives and World Health Organization recommendations for CYD-TDV dengue vaccine. J Infect Dis, 2016, 10.1093/infdis/jiw341 published online Aug 5.
40. 40 Weaver, SC, Osorio, JE, Livengood, JA, Chen, R, Stinchcomb, DT, Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines 11 (2012), 1087–1101.
41. 41 Chang, LJ, Dowd, KA, Mendoza, FH, with the VRC 311 Study Team. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 384 (2014), 2046–2052.
42. 42 Messina, JP, Brady, OJ, Pigott, DM, et al. The many projected futures of dengue. Nat Rev Microbiol 13 (2015), 230–239.
43. 43 Golding, N, Wilson, AL, Moyes, CL, et al. Integrating vector control across diseases. BMC Med, 13, 2015, 249.